The amylin receptors (AMYRs) are heterodimers of the calcitonin receptor that are bound to by amylin with high affinity and consist of AMY1, AMY2, and AMY3.
[1][2] Amylin mimetics that are agonists at the amylin receptors are being developed as therapies for diabetes and obesity, and one, pramlintide, has been FDA approved.
[3][4] The AMY1 receptor may be activated by both amylin and the calcitonin gene-related peptide (CGRP) and could play a role in the effects of CGRP receptor antagonists developed for migraine.
[5][6] Dual agonists of the amylin and calcitonin receptors (DACRAs) are under development for obesity.
[7] Amylin and its receptors are believed to play a role in Alzheimer's disease.